Last reviewed · How we verify
Phosphorus binder
Phosphorus binders reduce serum phosphate levels by binding dietary phosphorus in the gastrointestinal tract, preventing its absorption.
Phosphorus binders reduce serum phosphate levels by binding dietary phosphorus in the gastrointestinal tract, preventing its absorption. Used for Hyperphosphatemia in patients with chronic kidney disease, Hyperphosphatemia in patients on dialysis.
At a glance
| Generic name | Phosphorus binder |
|---|---|
| Also known as | Lanthanum Carbonate, Calcium Acetate |
| Sponsor | Salem Veterans Affairs Medical Center |
| Drug class | Phosphorus binder |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
Phosphorus binders are compounds that form complexes with dietary phosphate in the GI lumen, making phosphorus unavailable for absorption. This reduces serum phosphate concentrations, which is critical in managing hyperphosphatemia in patients with chronic kidney disease or end-stage renal disease who cannot adequately excrete phosphorus through the kidneys.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease
- Hyperphosphatemia in patients on dialysis
Common side effects
- Gastrointestinal disturbances (nausea, constipation, diarrhea)
- Hypercalcemia
- Abdominal discomfort
Key clinical trials
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis (PHASE3)
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China (PHASE3)
- Phosphorus Education and Adherence in Hemodialysis Patients (NA)
- Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial (PHASE1, PHASE2)
- The Effect of Renastart Formula Supplementation in Children With Acute Kidney Injury in Maintaining Normal Serum Electrolytes Levels (NA)
- A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients (PHASE2)
- Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
- A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |